Dose intensity and autologous stem cell transplantation as salvage therapy for pediatric primary CNS malignancies
Seiji Kojima,1 Andrei Cucuianu,2,3 Yoshiyuki Takahashi,1 Ioana Berindan-Neagoe,4–6 Ioan-Stefan Florian,7 Delia Dima,2 Ciprian Tomuleasa2,4 1Department of Paediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan; 2Department of Hematology, Ion Chiricuta Oncology Institute...
Guardado en:
Autores principales: | Kojima S, Cucuianu A, Takahashi Y, Berindan-Neagoe I, Florian IS, Dima D, Tomuleasa C |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/fba72393f1934b7795a25aa9deb234c3 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Sorafenib for the treatment of solid malignancies: what about the cancer microenvironment?
por: Tomuleasa C, et al.
Publicado: (2013) -
MRI-based identification of undifferentiated cells: looking at the two faces of Janus
por: Tomuleasa C, et al.
Publicado: (2014) -
IMMUNE STATE IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES AT LATE TERMS AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: N. V. Minaeva, et al.
Publicado: (2014) -
Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells
por: Fabio Guolo, et al.
Publicado: (2021) -
A randomized, non-inferiority study comparing efficacy and safety of a single dose of pegfilgrastim versus daily filgrastim in pediatric patients after autologous peripheral blood stem cell transplant.
por: Simone Cesaro, et al.
Publicado: (2013)